FY2025 Earnings Estimate for LENZ Issued By Leerink Partnrs

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Equities research analysts at Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for shares of LENZ Therapeutics in a research note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per share of ($2.65) for the year, down from their prior forecast of ($2.40). The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. Leerink Partnrs also issued estimates for LENZ Therapeutics’ FY2026 earnings at ($2.70) EPS and FY2028 earnings at $1.35 EPS.

Separately, HC Wainwright reiterated a “buy” rating and set a $38.00 target price on shares of LENZ Therapeutics in a research note on Thursday, November 7th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $35.40.

LENZ Therapeutics Price Performance

Shares of NASDAQ:LENZ opened at $25.48 on Friday. LENZ Therapeutics has a 52 week low of $14.42 and a 52 week high of $38.93. The company’s 50 day moving average is $29.69 and its two-hundred day moving average is $26.72.

LENZ Therapeutics (NASDAQ:LENZ) last issued its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.09. During the same quarter last year, the firm posted ($1.33) earnings per share.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new stake in LENZ Therapeutics during the 4th quarter worth $29,000. SG Americas Securities LLC acquired a new stake in shares of LENZ Therapeutics in the 3rd quarter valued at about $107,000. China Universal Asset Management Co. Ltd. purchased a new position in LENZ Therapeutics during the 4th quarter worth approximately $168,000. Squarepoint Ops LLC acquired a new position in LENZ Therapeutics during the second quarter worth approximately $181,000. Finally, MetLife Investment Management LLC acquired a new position in LENZ Therapeutics during the third quarter worth approximately $182,000. Institutional investors and hedge funds own 54.32% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.